SEP 06, 2016 06:30 PM PDT

Immune Biomarkers for Idiopathic Pulmonary Fibrosis

WRITTEN BY: Kara Marker
There’s no cure for idiopathic pulmonary fibrosis (IPF), and the disease gets irreversibly worse as it progresses. As scientists frantically look for biomarkers to catch the disease early and begin treating symptoms, a new study shows that biomarkers for IPF may be the same as those for some types of cancer.
Staining of surface molecules (CD11 in red, CD33 in green) on cells in lung tissue, nuclei in blue. MDSC are positive for both surface markers and consequently appear orange (arrow).
For people with IPF, usually older adults, their lung tissue becomes increasingly scarred over time. On average, people with IPF only live about three to five years after their diagnosis. Cause of death usually comes from respiratory failure, pulmonary hypertension, heart failure, pulmonary embolism, pneumonia, or lung cancer. Medical professionals believe that although the disease seems to be incurable, identifying patients as early as possible will give them the best chance of living longer and have a fuller life.

From the German Research Center for Environmental Health in a study published in the European Respiratory Journal, scientists discovered a connection between myeloid-derived suppressor cells (MDSCs) in the blood and incidence of IPF. The higher the number of MDSCs, the more limited the lung function IPF patients had.

“MDSC are primarily found in fibrotic niches of IPF lungs characterized by increased interstitial tissue and scarring, that is, in regions where the disease is very pronounced,” said Professor Oliver Eickelberg, study leader.

MDSCs are capable of suppressing the T cell response, an ability that is helpful in regulating the immune response but not desirable in cases of cancer or infection. High levels of MDSC activity are known to contribute to a poor prognosis in certain instances of cancer, and Eickelberg’s team seemed to be on the verge of discovering a similar contribution in cases of IPF.

Eickelberg and his team looked at blood samples of 170 study participants, with almost half being IPF patients. They analyzed the samples, looking for lymphocytes like MDSCs that could be linked to IPF in some way. After successfully identifying a significantly higher count of MDSCs in IPF patients versus health control patients, the researchers also saw an inverse relationship existing between lung function and levels of circulating MDSCs. However, the relationship appears to be unique to IPF patients; no inverse correlation was found in patients with chronic obstructive pulmonary disease (COPD) or other interstitial lung diseases.

The researchers also measured gene activity common in immune cells, and found that immune-associated genes were expressed less frequently in blood samples with high levels of MDSCs. Observing human lung tissue from IPF patients also provided evidence supporting their claim that MDSCs were compromising the immune system, exacerbating cases of IPF.

Next, the team plans to determine how the presence of MDSCs in high quantities in the blood can be used as a biomarker for IPF, looking at how soon IPF could be diagnosed based on MDSC presence. Additionally, researchers will explore the possibility of suppressing accumulation of MDSCs as a potential treatment option for IPF.
 


Sources: National Heart, Lung, and Blood Institute, Nature Reviews ImmunologyHelmholtz Zentrum München
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
OCT 08, 2018
Immunology
OCT 08, 2018
Nuclear Imaging: The Next Generation of Biopsy
A team of researchers has published their work in the Journal of Nuclear Medicine describing techniques with PET imaging as an alternative to biopsy methods....
OCT 23, 2018
Immunology
OCT 23, 2018
Missense Immune Disruption
A point mutation has caused a de novo immune deficiency observed in two patients...
NOV 19, 2018
Cell & Molecular Biology
NOV 19, 2018
How Mitochondria can Help the Cell Fight Pathogens
Some pathogens can get around out bodies' natural defense mechanisms. So our body developed a Plan B....
NOV 30, 2018
Immunology
NOV 30, 2018
Aspirin May Impove MS Symptoms
The medical benefits of aspirin have been known since ancient times. Hippocrates, c. 400 BC, prescribed the salicylate-rich bark and leaves of the willow t...
DEC 09, 2018
Immunology
DEC 09, 2018
A Better Human Immune System: In Mice
We've cured cancer and autoimmune disease in mice many times over....
DEC 18, 2018
Immunology
DEC 18, 2018
Enhancing Antibody Validation and Reproducibility
Many immunological technologies are only as good as the antibody being used for antigen detection. As such, there is enormous value with providing the scie...
Loading Comments...